Loading...
Market
Story
Pfizer's Talzenna-Xtandi Combo Significantly Prolongs Survival in Final Phase 3 Prostate Cancer Study
Oct 10, 2024, 10:55 AM
Pfizer announced that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) significantly extended overall survival in men with metastatic castration-resistant prostate cancer (mCRPC), according to the final prespecified overall survival analysis of the phase 3 TALAPRO-2 trial. The study demonstrated that the drug combination significantly prolonged patients' lives compared to enzalutamide alone, offering a promising new treatment option for this aggressive form of prostate cancer.
View original story
Similar markets
None • 25%
One • 25%
Two • 25%
Three or more • 25%
None • 25%
1 additional indication • 25%
2 additional indications • 25%
3 or more additional indications • 25%
None • 25%
1-2 • 25%
3-4 • 25%
5 or more • 25%
None • 25%
1 • 25%
2 • 25%
3 or more • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
None • 25%
1 to 2 • 25%
3 to 4 • 25%
More than 4 • 25%
No new competitors • 25%
1 new competitor • 25%
2 new competitors • 25%
3 or more new competitors • 25%
0-1 new treatments • 25%
2-3 new treatments • 25%
4-5 new treatments • 25%
More than 5 new treatments • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%